CDSCO's Drug Quality Alert: What It Means for Pharmaceutical Manufacturers

CDSCO — the Central Drugs Standard Control Organisation — periodically publishes nationwide drug quality alerts listing medicines and cosmetics that have failed quality testing under its market surveillance programme. Each alert can have far-reaching legal consequences for the manufacturers, distributors, and wholesalers of the listed products. Advocate Srijan Tiwari, drug and cosmetics law specialist at the Delhi High Court, breaks down what these alerts mean and what companies must do.

What is the CDSCO Drug Quality Alert?

Under India's drug market surveillance system, CDSCO collects drug samples from the open market — from pharmacies, hospitals, and distributors — and sends them to government testing laboratories across the country. When a sample is found to be Not of Standard Quality (NSQ), spurious, adulterated, or misbranded, CDSCO's Drug Alert Management System issues a nationwide alert.

These alerts are published on CDSCO's website and are accessible to state drug authorities, healthcare providers, and the public. The alerts identify the specific drug product (by brand name, manufacturer, and batch number), the nature of the quality failure, and the name of the testing laboratory that identified the problem.

Once a product appears on a CDSCO drug quality alert, the consequences escalate rapidly. State drug authorities issue Show Cause Notices (SCNs) to manufacturers and distributors. Recall orders follow. In many cases, criminal prosecution under the Drugs and Cosmetics Act, 1940 is initiated. Advocate Srijan Tiwari has represented pharmaceutical corporations facing these cascading consequences at the Delhi High Court and trial courts across Delhi.

The 2026 Drug Quality Surveillance — A More Aggressive Enforcement Posture

The pattern of CDSCO's drug quality alerts in 2025–26 reveals a markedly more aggressive enforcement posture from the DCGI's office. Several trends are worth noting from Advocate Srijan Tiwari's practice perspective:

• Wider product coverage: Quality alerts now cover not just scheduled drugs but also cosmetics products, nutraceuticals sold as drugs, and Ayurvedic formulations that straddle the drug-cosmetics boundary.
• Faster state follow-up: State drug authorities are acting on CDSCO alerts within days — not months — which means companies have very little time to respond before a prosecution notice arrives.
• Cross-state coordination: Manufacturers in one state whose products are flagged in another state's market surveillance are now being co-prosecuted in multiple jurisdictions simultaneously.
• Expanded manufacturer liability: CDSCO is now pursuing not just the holding manufacturing licence holder but also loan licence manufacturers, contract manufacturers, and marketing authorisation holders.

Immediate Legal Exposure When a Product Is Listed

When a pharmaceutical company's product appears on a CDSCO drug quality alert, the following legal exposures materialise immediately:

1. Show Cause Notice from state drug authority: Why the product should not be recalled and the manufacturing licence not suspended or cancelled.
2. Product seizure from market: Drug inspectors are authorised to seize remaining stocks of the flagged batch from the supply chain.
3. Criminal prosecution under the D&C Act: For NSQ findings, prosecution under Section 27 is mandatory — there is no discretion to waive prosecution once an NSQ finding is recorded.
4. Recall order and notification: CDSCO or the state drug authority may issue a mandatory recall order requiring the manufacturer to withdraw the product from the entire supply chain at their cost.
5. Licence suspension or cancellation: In serious cases — particularly where the NSQ finding relates to a life-saving drug or where the quality failure is egregious — the manufacturing licence can be suspended pending inquiry.

The First 72 Hours: What Advocate Srijan Tiwari Recommends

When Advocate Srijan Tiwari is retained by a pharmaceutical company whose product has appeared on a CDSCO drug quality alert, the first 72 hours are critical. Here is the immediate action framework:

Hour 1–12: Secure all batch documentation. Batch Manufacturing Records (BMR), Batch Packing Records (BPR), QC test reports for the flagged batch, In-Process Quality Control (IPQC) checks — all of these must be secured and preserved. These documents are the foundation of the defence.

Hour 12–24: Locate the retained sample. Rule 57 of the D&C Rules requires that a portion of the drug sample collected by the Drug Inspector be given to the manufacturer. This retained sample must be located and arrangements made for its counter-analysis at the Central Drugs Laboratory (CDL) in Kolkata. The application for CDL counter-analysis must be filed promptly.

Hour 24–48: Respond to the state drug authority. A show cause notice response must be filed — this is not just a procedural requirement. The quality of this response often determines whether the state drug authority proceeds with criminal prosecution or takes a more measured regulatory approach. Advocate Srijan Tiwari drafts these responses with a dual objective: satisfying the regulatory authority while preserving the legal defences for subsequent court proceedings.

Hour 48–72: Assess the voluntary recall question. This is one of the most difficult strategic decisions a pharmaceutical company faces. A voluntary recall — while admitting the quality issue for product safety purposes — can demonstrate good faith and reduce criminal exposure. The decision must be made carefully in consultation with drug law counsel who understands both the legal and reputational dimensions.

Challenging a CDSCO Quality Alert Listing — Is It Possible?

Yes — and Advocate Srijan Tiwari has successfully done so on behalf of corporate clients. A CDSCO drug quality alert listing can be challenged on several grounds:

• The sample tested was not drawn from the actual manufacturing batch or lot
• The testing laboratory did not follow pharmacopoeial methods correctly
• The alleged quality failure is within the acceptable variation range when correctly calculated
• The product had already exceeded its shelf life when sampled — making the quality result irrelevant to the manufacturer
• The CDL counter-analysis confirms the product conforms to standards

Where a CDL counter-analysis report comes back conforming, Advocate Srijan Tiwari files a representation with CDSCO's Drug Alert Management System requesting removal of the product from the quality alert list and cessation of criminal proceedings. Delhi High Court writ petitions have also been filed challenging quality alert listings that are factually or procedurally incorrect.

Building a Proactive CDSCO Alert Response System

The best defence against a CDSCO drug quality alert is a proactive one. Advocate Srijan Tiwari advises pharmaceutical corporations to:

• Monitor CDSCO's Drug Alert Management System regularly for their product categories
• Maintain complete and well-organised batch documentation that can be produced quickly in response to any alert
• Retain standing counsel at the Delhi High Court with exclusive drug law expertise — not general corporate counsel who are not equipped for regulatory prosecution defence
• Conduct internal mock audits of sampling and quality documentation readiness
• Ensure the company's Quality Control and Quality Assurance teams are familiar with the legal framework for responding to government sampling

Advocate Srijan Tiwari offers corporate retainer arrangements for pharmaceutical companies that want standing drug law counsel — the equivalent of having a specialist on call for the inevitable moment when a regulatory action materialises. Contact his Delhi High Court office at 9899966225 or srijantiwari@hotmail.com.